Literature DB >> 8094961

Lamotrigine--antiparkinsonian activity by blockade of glutamate release?

F Zipp1, H Baas, P A Fischer.   

Abstract

Recent experiments provide evidence that the NMDA-antagonist MK-801 has a locomotor-stimulating effect in monoamine-depleted rodents. These findings are based upon a hypothetical pathway-circuit including the basal ganglia as a model reflecting hypo- and hyperkinetic movement disorders. We have treated 5 patients suffering from Parkinson's disease with the antiepileptic drug "lamotrigine" which does not appear to be an NMDA-antagonist but acts functionally as a glutamate antagonist by inhibition of presynaptic glutamate release.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8094961     DOI： 10.1007/bf02260916

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN： 0936-3076


  7 in total

1.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons.

Authors:  P Calabresi; D Centonze; G A Marfia; A Pisani; G Bernardi
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

3.  A case of lamotrigine-induced excessive involuntary eye blinking.

Authors:  Dong-Gun Kim; Seung-Hun Oh; Ok Joon Kim
Journal:  J Clin Neurol       Date:  2007-06-20       Impact factor: 3.077

Review 4.  Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.

Authors:  K L Goa; S R Ross; P Chrisp
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

5.  Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).

Authors:  J Staedt; G Stoppe; A Kögler; H Riemann; G Hajak; D L Munz; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Lamotrigine in the treatment of nocturnal myoclonus syndrome (NMS): two case reports.

Authors:  J Staedt; G Stoppe; H Riemann; G Hajak; E Rüther; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

7.  The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole.

Authors:  G Rammes; W Zieglgänsberger; C G Parsons
Journal:  J Neural Transm (Vienna)       Date:  2008-05-21       Impact factor: 3.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.